Molecular signatures of chronic myeloid leukemia stem cells

BCR-ABL tyrosine kinase inhibitors (TKIs) are effective in controlling Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) are unlikely to cure the disease because TKIs are unable to eradicate leukemia stem cells (LSCs) responsible for the disease relapse even after tyrosine kinase inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yaoyu, Li, Shaoguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177606/
https://www.ncbi.nlm.nih.gov/pubmed/24252550
http://dx.doi.org/10.1186/2050-7771-1-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177606/
https://www.ncbi.nlm.nih.gov/pubmed/24252550
http://dx.doi.org/10.1186/2050-7771-1-21

Ejemplares similares